SG StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceuticals & Medical Research

NaN

0.000-0.96%

Number of Gainers:- -

Number of Losers:3

Number of Flat:3

PE:- -

High:NaN

Open:NaN

Low:NaN

Close:NaN

Volume:9.13M

Turnover:7.26M

Market Cap:6.81B

Float Cap:3.98B

Loading ...

Hyphens Pharma FY2025 profit after tax falls 43.6% to SGD 6.1 million

Hyphens Pharma International Ltd FY Revenue SGD 177.4 Million

THOMSON REUTERS

Hyphens Pharma International - Proposes a Final Dividend of 1.5 Singapore Cents for FY2025

THOMSON REUTERS

IX Biopharma completes S$6 million private placement of 75.8 million new shares

IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Proposed Placement Completion

THOMSON REUTERS

Singapore Shares Close Marginally Higher Despite Regional Losses; OUE REIT Climbs 4%

iX Biopharma Receives In-Principle Approval for Listing, Quotation of New Shares

MT Newswires Live

IX Biopharma Secures SGX Approval for S$6 Million Share Placement

IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Receipt of Lqn

THOMSON REUTERS

IX Biopharma Ltd. Request for Lifting of Trading Halt - Sponsor's Statement

THOMSON REUTERS

BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share

IX Biopharma - to Raise at Least S$6 Mln via Placement at S$0.198 per Share

THOMSON REUTERS

IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds of No Less Than S$6,000,000 - Entry Into Placement Agrt

THOMSON REUTERS

IX Biopharma Ltd. U.S. Government Awards IX Biopharma US$41 Million Contract to Fund Development of Wafermine

THOMSON REUTERS

3 Singapore Dividend Stocks to Watch During CNY

The Smart Investor

IX Biopharma Ltd. Request for Trading Halt

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK6506/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK6506","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","market":"SI","secType":"PLATE","nameCN":"Pharmaceuticals & Medical Research","latestPrice":2.9878898e-8,"timestamp":1772010726347,"preClose":3.0169275e-8,"halted":0,"volume":9134600,"delay":0,"changeRate":-0.009625,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-25 17:16:00 SGT","open":3.015298e-8,"high":3.0327e-8,"low":2.9836944e-8,"amount":7257218,"amplitude":0.016244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772065800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771979400000,1771992000000],[1771995600000,1772010960000]],"pbRate":1.635836,"peRate":10.464967,"turnoverRate":0.00765,"increases":0,"decrements":3,"flats":4,"marketCap":6812056808,"floatMarketCap":3978755699.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","high":3.0327e-8,"amplitude":0.016244,"preClose":3.0169275e-8,"low":2.9836944e-8,"pbRate":"1.635836","latestPrice":2.9878898e-8,"volume":9134600,"delay":0,"open":3.015298e-8,"prevYearClose":1.4808467e-7,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0,"secType":"PLATE","market":"SI","turnoverRate":0.00765,"peRate":10.464967,"marketCap":6812056808,"floatMarketCap":3978755699.75,"timestamp":1772010726347,"nameCN":"Pharmaceuticals & Medical Research"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK6506\",,,,undefined,":{"bkCode":"BK6506","up":0,"down":3,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK6506\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613442794","title":"Hyphens Pharma FY2025 profit after tax falls 43.6% to SGD 6.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613442794","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613442794?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:01","pubTimestamp":1771927315,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyphens Pharma International Ltd. published the original content used to generate this news brief via Singapore Exchange Limited   on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLb4TFx8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013460.SGD","BK6523","LU0188438112.USD","SG9999000343.SGD","BK6506","LU1119993845.HKD","LU0192582467.USD","LU0877626530.USD","SG9999013486.USD","SGXZ27511609.SGD","LU0532188223.SGD","SG9999003826.SGD","LU2242652126.USD","LU0441851309.USD","LU0831103253.SGD","BK6516","LU1920062954.HKD","SG9999006266.SGD","LU0898667661.SGD","LU2401740654.USD","LU1839390173.USD","SG9999001846.SGD","SGXZ58947870.SGD","LU0326948709.USD","BK6079","BK6033","SG9999001135.SGD","SG9999013478.USD","LU2242646235.USD","1J5.SI","SG9999014484.SGD","LU2242646821.SGD","SG9999014492.USD","IE00BKZH1Z71.USD","LU1920063259.USD","SG9999004360.SGD","LU0205439572.USD","SG9999016042.SGD"],"gpt_icon":0},{"id":"2613679441","title":"Hyphens Pharma International Ltd FY Revenue SGD 177.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613679441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613679441?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:01","pubTimestamp":1771927294,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX820CC9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","BK6079","1J5.SI"],"gpt_icon":0},{"id":"2613415794","title":"Hyphens Pharma International  - Proposes a Final Dividend of 1.5 Singapore Cents for FY2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2613415794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613415794?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:01","pubTimestamp":1771927294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX820CC9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","BK6506","1J5.SI"],"gpt_icon":0},{"id":"2613997417","title":"IX Biopharma completes S$6 million private placement of 75.8 million new shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613997417","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613997417?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:28","pubTimestamp":1771925319,"startTime":"0","endTime":"0","summary":"IX Biopharma Ltd. said it has completed a private placement on Feb. 24, 2026, issuing 75.8 million new shares to raise gross proceeds of no less than S$6 million. Following the allotment, the company’s issued shares increased to 1,036,295,895 from 960,495,895, with the new shares ranking equally with existing shares. The shares are expected to be listed and quoted on SGX-ST Catalist around Feb. 26, 2026, with trading to begin at 9:00 a.m. the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited   on February 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL181TFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IX Biopharma completes S$6 million private placement of 75.8 million new shares","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003826.SGD","LU0877626530.USD","LU2242646821.SGD","SG9999006266.SGD","LU0205439572.USD","LU0188438112.USD","LU1920063259.USD","SGXZ27511609.SGD","42C.SI","SG9999001135.SGD","LU1119993845.HKD","SG9999004360.SGD","LU1920062954.HKD","SG9999013460.SGD","LU0192582467.USD","SG9999001846.SGD","SG9999016042.SGD","LU0898667661.SGD","LU2242652126.USD","SG9999014492.USD","SGXZ58947870.SGD","LU0441851309.USD","LU2401740654.USD","LU0831103253.SGD","BK6516","SG9999013486.USD","LU1839390173.USD","BK6523","BK6506","BK6079","SG9999014484.SGD","LU0326948709.USD","LU0532188223.SGD","SG9999000343.SGD","LU2242646235.USD","IE00BKZH1Z71.USD","SG9999013478.USD","BK6033"],"gpt_icon":0},{"id":"2613799798","title":"IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Proposed Placement Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2613799798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613799798?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:28","pubTimestamp":1771925309,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUEGB98J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":0},{"id":"2612263541","title":"Singapore Shares Close Marginally Higher Despite Regional Losses; OUE REIT Climbs 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612263541","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612263541?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:50","pubTimestamp":1771581000,"startTime":"0","endTime":"0","summary":"Singapore shares closed the week higher, with a modest uptick building on yesterday's powerful 1.3% surge, which saw the index crossing the 5,000 mark on Thursday.The Straits Times Index , a key benchmark for the Singapore Exchange, ranged between 4,993.43 and 5,024.57 throughout the day. It ended the session at 5,017.60, up 16.04 points or 0.3% compared to Thursday's close.On the corporate front, shares of OUE REIT  were up over 4% at the close after the REIT said that its subsidiary, OUB Centre, which holds an 81.54% stake in One Raffles Place, is conducting an exercise with United Overseas Bank  to assess market interest in the property.Nera Telecommunications  shares closed over 4% higher as it secured a three-year contract worth around SG$2.4 million from an institutional asset manager.Meanwhile, shares of iX Biopharma  were up over 2% at the close as it received in-principle approval from the Singapore Exchange Securities Trading for the listing and quotation of up to 75.8 millio","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6072","BK6005","N01.SI","BK6506","42C.SI","STI.SI","BK6079","BK6512","TS0U.SI","BK6515"],"gpt_icon":0},{"id":"2612847255","title":"iX Biopharma Receives In-Principle Approval for Listing, Quotation of New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612847255","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612847255?lang=en_us&edition=fundamental","pubTime":"2026-02-20 11:41","pubTimestamp":1771558905,"startTime":"0","endTime":"0","summary":"iX Biopharma  received an in-principle approval from the Singapore Exchange Securities Trading for the listing and quotation of up to 75.8 million shares to raise around SG$6 million, according to a Thursday filing with the Singapore Exchange.Shares of the specialty pharmaceutical and nutraceutical company were up over 2% in Friday trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6523","LU0188438112.USD","LU0326948709.USD","LU0877626530.USD","SG9999013486.USD","LU2242646821.SGD","SG9999003826.SGD","SG9999016042.SGD","SGXZ58947870.SGD","LU0192582467.USD","SG9999001846.SGD","SG9999006266.SGD","LU1839390173.USD","LU0441851309.USD","LU1920063259.USD","BK6033","LU0205439572.USD","LU1920062954.HKD","LU2242652126.USD","SG9999001135.SGD","SGXZ27511609.SGD","LU2401740654.USD","BK6079","42C.SI","IE00BKZH1Z71.USD","LU2242646235.USD","SG9999013478.USD","LU0831103253.SGD","BK6516","SG9999004360.SGD","SG9999014484.SGD","LU1119993845.HKD","BK6506","SG9999000343.SGD","SG9999014492.USD","LU0898667661.SGD","SG9999013460.SGD","LU0532188223.SGD"],"gpt_icon":0},{"id":"2612806409","title":"IX Biopharma Secures SGX Approval for S$6 Million Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2612806409","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612806409?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:46","pubTimestamp":1771497992,"startTime":"0","endTime":"0","summary":"IX Biopharma Ltd. said it has received in-principle approval from SGX-ST for the listing and quotation of up to 75.8 million new shares to be issued under its proposed placement, which is intended to raise gross proceeds of at least S$6 million. The company noted the placement remains subject to the fulfilment of conditions under the placement agreement and compliance with SGX-ST listing requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited   on February 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL9jJHrj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6033","LU2401740654.USD","SG9999004360.SGD","SG9999013478.USD","LU0192582467.USD","LU2242646235.USD","LU0898667661.SGD","BK6079","LU0831103253.SGD","SG9999000343.SGD","SG9999014484.SGD","BK6506","LU0188438112.USD","LU2242646821.SGD","SG9999001135.SGD","LU0441851309.USD","SG9999001846.SGD","LU1920063259.USD","LU2242652126.USD","LU1839390173.USD","42C.SI","SG9999016042.SGD","LU0532188223.SGD","LU1920062954.HKD","LU1119993845.HKD","SG9999014492.USD","SGXZ27511609.SGD","SG9999006266.SGD","LU0326948709.USD","BK6523","BK6516","LU0877626530.USD","IE00BKZH1Z71.USD","SG9999003826.SGD","SG9999013486.USD","LU0205439572.USD","SG9999013460.SGD","SGXZ58947870.SGD"],"gpt_icon":0},{"id":"2612409872","title":"IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Receipt of Lqn","url":"https://stock-news.laohu8.com/highlight/detail?id=2612409872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612409872?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:46","pubTimestamp":1771497984,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUE34JYLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"2611875581","title":"IX Biopharma Ltd. Request for Lifting of Trading Halt - Sponsor's Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2611875581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611875581?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:18","pubTimestamp":1770963538,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUE5DKTZ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"2610937978","title":"BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937978","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937978?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:42","pubTimestamp":1770910969,"startTime":"0","endTime":"0","summary":"BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per ShareFeb 12 (Reuters) - IX Biopharma Ltd IXBI.SI:TO RAISE AT LEAST S$6 MILLION VIA PLACEMENT AT S$0.198 PER SHAREFurther company coverage: IXBI.SI ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"2610942326","title":"IX Biopharma - to Raise at Least S$6 Mln via Placement at S$0.198 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610942326","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610942326?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:53","pubTimestamp":1770893607,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["42C.SI","BK6079","BK6506"],"gpt_icon":0},{"id":"2610942312","title":"IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds of No Less Than S$6,000,000 - Entry Into Placement Agrt","url":"https://stock-news.laohu8.com/highlight/detail?id=2610942312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610942312?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:52","pubTimestamp":1770893567,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUE97XJWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["42C.SI","BK6079","BK6506"],"gpt_icon":0},{"id":"2610012944","title":"IX Biopharma Ltd. U.S. Government Awards IX Biopharma US$41 Million Contract to Fund Development of Wafermine","url":"https://stock-news.laohu8.com/highlight/detail?id=2610012944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610012944?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:45","pubTimestamp":1770893153,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUE8HZYWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","42C.SI","BK6079"],"gpt_icon":0},{"id":"2610299476","title":"3 Singapore Dividend Stocks to Watch During CNY","url":"https://stock-news.laohu8.com/highlight/detail?id=2610299476","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610299476?lang=en_us&edition=fundamental","pubTime":"2026-02-12 11:30","pubTimestamp":1770867000,"startTime":"0","endTime":"0","summary":"Discover three Singapore dividend stocks hitting their stride this Chinese New Year.","market":"us","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/02/Vicom-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/02/Vicom-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/3-singapore-dividend-stocks-to-watch-during-cny/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/3-singapore-dividend-stocks-to-watch-during-cny/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK6029","LU0188438112.USD","SG9999016042.SGD","SG9999001846.SGD","SG9999001135.SGD","SG9999013460.SGD","LU2242646821.SGD","LU0441851309.USD","LU0532188223.SGD","LU0831103253.SGD","LU2401740654.USD","SG9999013486.USD","ODBU.SI","SG9999004360.SGD","SG9999000343.SGD","IE0031814969.USD","BK6079","BK6033","SG9999014492.USD","SGXZ58947870.SGD","BK6137","BK6521","LU0192582467.USD","SG9999006266.SGD","SG9999013478.USD","BK6506","BK6516","LU0326948709.USD","LU0898667661.SGD","LU2242646235.USD","U13.SI","LU1920062954.HKD","SGXZ27511609.SGD","SG9999003826.SGD","SG9999014484.SGD","BK6054","LU0205439572.USD","WJP.SI","LU1119993845.HKD","LU1920063259.USD","BK6011","BK6512","BK6523","LU0877626530.USD","LU2242652126.USD","IE00BKZH1Z71.USD","BK6520","LU1839390173.USD"],"gpt_icon":0},{"id":"2610602911","title":"IX Biopharma Ltd. Request for Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2610602911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610602911?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:31","pubTimestamp":1770784317,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUE3BQKS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["42C.SI","BK6506","BK6079"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}